RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth

Shakuntala Kondraganti, Christopher S. Gondi, Ian McCutcheon, Dzung H. Dinh, Meena Gujrati, Jasti S. Rao, William C. Olivero

Research output: Contribution to journalArticle

Abstract

In recent years, RNA interference (RNAi) has emerged as an effective method to target specific genes for silencing. Several groups are actively exploring the use of small interfering RNA (siRNA) for therapeutic applications to treat cancer. Our previous studies have demonstrated the inhibition of various proteases, including serine proteases, cysteine proteases and matrix metalloproteases, via RNA interference (RNAi) in gliomas. Similar to gliomas, malignant meningiomas also exhibit elevated protease levels in comparison to normal brain and benign meningiomas. Here, we used siRNA to simultaneously target urokinase plasminogen activator (uPA) and its receptor, uPAR. A human CMV promoter-driven mammalian expression vector (pU2) was used to produce hairpin double-stranded RNA (hp RNA) to target uPA and uPAR. As determined by Western blotting and fibrin zymography, pU2 effectively inhibited uPAR protein levels and uPA enzymatic activity in meningioma cells (IOMM-Lee). In vitro studies (Matrigel invasion and spheroid migration) revealed reduced meningioma cell invasion and migration. Intratumoral injections of the plasmid vector expressing siRNA for uPA and uPAR resulted in regression of pre-established, subcutaneous tumors in mice. In addition, in vivo studies of mice injected with pU2-transfected meningioma cells revealed inhibition of intracranial tumor formation. These findings suggest that siRNA can be used as a potent and specific therapeutic tool for the treatment of malignant meningiomas in humans.

Original languageEnglish (US)
Pages (from-to)1353-1360
Number of pages8
JournalInternational Journal of Oncology
Volume28
Issue number6
StatePublished - Jun 2006

Fingerprint

Urokinase Plasminogen Activator Receptors
Meningioma
RNA Interference
Down-Regulation
Small Interfering RNA
Plasminogen Activators
Urokinase-Type Plasminogen Activator
Growth
Neoplasms
Glioma
Peptide Hydrolases
Cysteine Proteases
Double-Stranded RNA
Metalloproteases
Serine Proteases
Gene Silencing
Fibrin
Cell Movement
Plasmids
Therapeutics

Keywords

  • Invasion
  • Meningioma
  • Migration
  • siRNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kondraganti, S., Gondi, C. S., McCutcheon, I., Dinh, D. H., Gujrati, M., Rao, J. S., & Olivero, W. C. (2006). RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth. International Journal of Oncology, 28(6), 1353-1360.

RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth. / Kondraganti, Shakuntala; Gondi, Christopher S.; McCutcheon, Ian; Dinh, Dzung H.; Gujrati, Meena; Rao, Jasti S.; Olivero, William C.

In: International Journal of Oncology, Vol. 28, No. 6, 06.2006, p. 1353-1360.

Research output: Contribution to journalArticle

Kondraganti, S, Gondi, CS, McCutcheon, I, Dinh, DH, Gujrati, M, Rao, JS & Olivero, WC 2006, 'RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth', International Journal of Oncology, vol. 28, no. 6, pp. 1353-1360.
Kondraganti, Shakuntala ; Gondi, Christopher S. ; McCutcheon, Ian ; Dinh, Dzung H. ; Gujrati, Meena ; Rao, Jasti S. ; Olivero, William C. / RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth. In: International Journal of Oncology. 2006 ; Vol. 28, No. 6. pp. 1353-1360.
@article{56aa67b9e004460abe0e9a5c1cefe126,
title = "RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth",
abstract = "In recent years, RNA interference (RNAi) has emerged as an effective method to target specific genes for silencing. Several groups are actively exploring the use of small interfering RNA (siRNA) for therapeutic applications to treat cancer. Our previous studies have demonstrated the inhibition of various proteases, including serine proteases, cysteine proteases and matrix metalloproteases, via RNA interference (RNAi) in gliomas. Similar to gliomas, malignant meningiomas also exhibit elevated protease levels in comparison to normal brain and benign meningiomas. Here, we used siRNA to simultaneously target urokinase plasminogen activator (uPA) and its receptor, uPAR. A human CMV promoter-driven mammalian expression vector (pU2) was used to produce hairpin double-stranded RNA (hp RNA) to target uPA and uPAR. As determined by Western blotting and fibrin zymography, pU2 effectively inhibited uPAR protein levels and uPA enzymatic activity in meningioma cells (IOMM-Lee). In vitro studies (Matrigel invasion and spheroid migration) revealed reduced meningioma cell invasion and migration. Intratumoral injections of the plasmid vector expressing siRNA for uPA and uPAR resulted in regression of pre-established, subcutaneous tumors in mice. In addition, in vivo studies of mice injected with pU2-transfected meningioma cells revealed inhibition of intracranial tumor formation. These findings suggest that siRNA can be used as a potent and specific therapeutic tool for the treatment of malignant meningiomas in humans.",
keywords = "Invasion, Meningioma, Migration, siRNA",
author = "Shakuntala Kondraganti and Gondi, {Christopher S.} and Ian McCutcheon and Dinh, {Dzung H.} and Meena Gujrati and Rao, {Jasti S.} and Olivero, {William C.}",
year = "2006",
month = "6",
language = "English (US)",
volume = "28",
pages = "1353--1360",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth

AU - Kondraganti, Shakuntala

AU - Gondi, Christopher S.

AU - McCutcheon, Ian

AU - Dinh, Dzung H.

AU - Gujrati, Meena

AU - Rao, Jasti S.

AU - Olivero, William C.

PY - 2006/6

Y1 - 2006/6

N2 - In recent years, RNA interference (RNAi) has emerged as an effective method to target specific genes for silencing. Several groups are actively exploring the use of small interfering RNA (siRNA) for therapeutic applications to treat cancer. Our previous studies have demonstrated the inhibition of various proteases, including serine proteases, cysteine proteases and matrix metalloproteases, via RNA interference (RNAi) in gliomas. Similar to gliomas, malignant meningiomas also exhibit elevated protease levels in comparison to normal brain and benign meningiomas. Here, we used siRNA to simultaneously target urokinase plasminogen activator (uPA) and its receptor, uPAR. A human CMV promoter-driven mammalian expression vector (pU2) was used to produce hairpin double-stranded RNA (hp RNA) to target uPA and uPAR. As determined by Western blotting and fibrin zymography, pU2 effectively inhibited uPAR protein levels and uPA enzymatic activity in meningioma cells (IOMM-Lee). In vitro studies (Matrigel invasion and spheroid migration) revealed reduced meningioma cell invasion and migration. Intratumoral injections of the plasmid vector expressing siRNA for uPA and uPAR resulted in regression of pre-established, subcutaneous tumors in mice. In addition, in vivo studies of mice injected with pU2-transfected meningioma cells revealed inhibition of intracranial tumor formation. These findings suggest that siRNA can be used as a potent and specific therapeutic tool for the treatment of malignant meningiomas in humans.

AB - In recent years, RNA interference (RNAi) has emerged as an effective method to target specific genes for silencing. Several groups are actively exploring the use of small interfering RNA (siRNA) for therapeutic applications to treat cancer. Our previous studies have demonstrated the inhibition of various proteases, including serine proteases, cysteine proteases and matrix metalloproteases, via RNA interference (RNAi) in gliomas. Similar to gliomas, malignant meningiomas also exhibit elevated protease levels in comparison to normal brain and benign meningiomas. Here, we used siRNA to simultaneously target urokinase plasminogen activator (uPA) and its receptor, uPAR. A human CMV promoter-driven mammalian expression vector (pU2) was used to produce hairpin double-stranded RNA (hp RNA) to target uPA and uPAR. As determined by Western blotting and fibrin zymography, pU2 effectively inhibited uPAR protein levels and uPA enzymatic activity in meningioma cells (IOMM-Lee). In vitro studies (Matrigel invasion and spheroid migration) revealed reduced meningioma cell invasion and migration. Intratumoral injections of the plasmid vector expressing siRNA for uPA and uPAR resulted in regression of pre-established, subcutaneous tumors in mice. In addition, in vivo studies of mice injected with pU2-transfected meningioma cells revealed inhibition of intracranial tumor formation. These findings suggest that siRNA can be used as a potent and specific therapeutic tool for the treatment of malignant meningiomas in humans.

KW - Invasion

KW - Meningioma

KW - Migration

KW - siRNA

UR - http://www.scopus.com/inward/record.url?scp=33747137698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747137698&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 1353

EP - 1360

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -